Comparison between Teamlease Services Buyback 2026 and Zydus Lifesciences Buyback 2026.
Teamlease Services Buyback 2026 is a Tender Offer buyback proposed to list at BSE, NSE while Zydus Lifesciences Buyback 2026 is a Tender Offer proposed to list at BSE, NSE.
| Teamlease Services Ltd | Zydus Lifesciences Ltd | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Logo |  |  | |||||||||
| Type of Buyback | Tender Offer | Tender Offer | |||||||||
| Listing At | BSE, NSE | BSE, NSE | |||||||||
| Face Value | ₹10 per share | ₹1 per share | |||||||||
| Buyback Price | ₹1600 per share | ₹1260 per share | |||||||||
| Issue Size | 14,87,500 shares | 87,30,158 shares | |||||||||
| Issue Size (Amount) | ₹238.00 Crores | ₹1,100.00 Crores | |||||||||
| Buyback Ratio |
Note:
| ||||||||||
| Registrar | MUFG Intime India Pvt.Ltd. | ||||||||||
| Lead Managers | ICICI Securities Ltd. | ||||||||||
| Necessity of the buyback | The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
|
Teamlease Services Buyback 2026 and Zydus Lifesciences Buyback 2026 buyback timetable. The investors should have the company's shares in their demat accounts as of the record date. Teamlease Services Buyback 2026 Buyback record date is . Zydus Lifesciences Buyback 2026 Buyback record date is May 29, 2026.
| Teamlease Services Ltd | Zydus Lifesciences Ltd | |
|---|---|---|
| Record Date | May 29, 2026 | |
| Offer Open Date | Jun 04, 2026 | |
| Offer Closure Date | Jun 10, 2026 | |
| Last date for receipt of tender forms | Jun 10, 2026 | |
| Finalisation of buyback | Jun 16, 2026 | |
| Last Date for settlment of bids | Jun 17, 2026 | |
| Last Date for extinguishment of shares | Jun 29, 2026 |
Comparison of Teamlease Services Buyback 2026 and Zydus Lifesciences Buyback 2026 financial data. The table below also includes a list of all relevant information like Stock Market Data, Compay Information, Lead Manager and Registrar.
| Teamlease Services Ltd | Zydus Lifesciences Ltd | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financial | Company Financials (Restated Consolidated)
| Company Financials (Restated Standalone)Zydus Lifesciences Ltd's revenue decreased by 17% and profit after tax (PAT) dropped by 38% between the financial year ending with March 31, 2026 and March 31, 2025.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock price at BSE | Stock price at BSE (in preceding 3 months)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock price at NSE | Stock price at NSE (in preceding 3 months)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
